TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03349866
Drug: Oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 130 mg/m2 Ivgtt d1 q3w
Study: NCT00895960
Drug: Dasatinib
Normalized name: Dasatinib
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Starting dose of 150 mg/day administered by mouth daily on Days 1 to 28 of every 28 day cycle, beginning on the first day of RT.
Study: NCT04196946
Drug: 250 mcg alfentanil
DrugBank: Alfentanil (DB00802)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Before operation each patient was informed about the use of patient controlled analgesia system and visual pain scale (VPS) for pain scoring. In operating room all patient was monitored using electrocardiography (ECG), noninvasive blood pressure. Before spinal anesthesia 10-15 ml/kg intravenous serum saline infusion was started. Group II received 10 mg hyperbaric bupivacaine (2 cc) and 250 mcg alfentanil (0.5 cc) intrathecally.
Study: NCT00895960
Drug: TMZ (Temozolomide)
Normalized name: TMZ
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 75 mg/m\^2 capsules daily by mouth for up to a maximum of 7 weeks beginning first day of RT until RT end followed by 4 weeks off then 150 mg/m\^2 daily on Days 1-5 of each 28 day study cycle and 200 mg/m\^2 daily of subsequent cycles.
Study: NCT00612508
Drug: Desogen (ethinyl estradiol and desogestrel)
Normalized name: Desowen
DrugBank: Desogestrel (DB00304)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 tablet every day; each tablet contains 0.15mg desogestrel and 0.03mg ethinyl estradiol
Study: NCT00612508
Drug: NuvaRing (ethinyl estradiol and etonogestrel)
Normalized name: ethinyl estradiol / etonogestrel Vaginal System [NuvaRing]
DrugBank: Etonogestrel (DB00294)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Place the ring in the vagina for 3 weeks, remove for one week. Repeat with new Ring
Study: NCT02008357
Drug: Solanezumab
Normalized name: Solanezumab
DrugBank: Solanezumab (DB11756)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered IV
Study: NCT00627536
Drug: Avotermin
Normalized name: avotermin
DrugBank: Avotermin (DB11955)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single intradermal injection of avotermin administered at the dose to both margins of a full-thickness incision immediately following closure.
Study: NCT03455439
Drug: Rivaroxaban (Xarelto, BAY59-7939)
Normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: As prescribed by the treating physician
Study: NCT04082910
Drug: Metoprolol
Normalized name: Metoprolol
DrugBank: Metoprolol (DB00264)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Metoprolol was given in patients who received CAR T cell therapy for CRS control or CRS precaution.
Study: NCT04082910
Drug: metoprolol, infliximab, etanercept, tocilizumab and/or other agents
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: During the term of metoprolol use, antibodies (infliximab, etanercept and tocilizumab) and/or other agents were not completely limited to be used under the consideration of clinical requirement for sufficient control of continuously progressed CRS.
Study: NCT02338934
Drug: Combination Cinacalcet with Vitamin D analogue
DrugBank: Cinacalcet (DB01012)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Depending on the iPTH level and the serum calcium level they will be started on Cinacalcet 25mg OD and active Vitamin D will be adjusted. If Serum Cal \<2.4 mmol/L - Start Cinacalcet 25mg OD \& Increase active Vit D by 1 mcg/dose 3x/week Increase active Vit D by 1 mcg/dose 3x/week or Serum Ca 2.4-2.54 mmol/L- Start Cinacalcet 25mg OD and Maintain active Vit D dose OR if \>2.54 mmol/L - Start Cinacalcet 25mg OD \& Maintain active Vit D dose. Then they will go to maintenance phase.
Study: NCT00755534
Drug: Irinotecan
Normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Irinotecan (IV) 150 mg/m2 on day 1 every two weeks until progression
Study: NCT00755534
Drug: Cetuximab
Normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Cetuximab(IV) 500 mg/m2 on day 1 every two weeks until progression
Study: NCT00755534
Drug: Oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oxaliplatin (I.V) 85 mg/m2 on day 1 every two weeks until progression
Study: NCT04852510
Drug: Metformin Versus a combination of Metformin and Thymoquinone (TQ)
Normalized name: metformin and ertugliflozin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Patients were divided into two groups (A and B) using a computer-based software Open Epi version 3.21. Patients in Group A, received Metformin 500 mg three times daily (5) with meals for 6 months (Metfor® 500 mg, Metformin hydrochloride tablets. TABUK Pharmaceutical. KSA). Patients in Group B, received a combination of Metformin 500 mg three times daily with meals (Metfor® 500 mg, Metformin hydrochloride tablets. TABUK Pharmaceutical. KSA) and Thymoquinone (TQ) in the form of Black Cumin oil (Cumin Mar® Black cumin oil 500 mg soft gel capsules, MARNYS. Spain) three times daily before meals for 6 months.
Study: NCT03242018
Drug: Sotagliflozin
Normalized name: sotagliflozin
DrugBank: Sotagliflozin (DB12713)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Sotagliflozin 200 mg, tablet, orally, once daily.
Study: NCT00819468
Drug: Teduglutide
Normalized name: Teduglutide
DrugBank: Teduglutide (DB08900)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Participants will receive 20 mg dose of lypholized powder of teduglutide mixed with sterile water and injected subcutaneously into the abdomen.
Study: NCT01810588
Drug: anti-thymocyte globulin (rabbit)
Normalized name: anti-thymocyte globulin (rabbit)
DrugBank: Antithymocyte immunoglobulin (rabbit) (DB00098)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administer 1.5 mg/kg/day intravenously x 3 days, total 4.5 mg/kg. ATG will be dosed according to actual body weight. The first dose will be infused over at least six hours, and subsequent doses over at least 4 hours. Pre-medications include acetaminophen 650 mg by mouth, diphenhydramine 25-50 mg by mouth or intravenously, and methylprednisolone 2 mg/kg (1 mg/ kg at the initiation and 1 mg/kg half-way through anti-thymocyte globulin administration).
Study: NCT00532571
Drug: CoQ10
Normalized name: CoQ10
DrugBank: Ubidecarenone (DB09270)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01969877
Drug: cetuximab
Normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT01969877
Drug: cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01241760
Drug: Ribavirin
Normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ribavirin (RBV) 1000-1200 milligram (mg) per day (weight dependent) twice daily regimen oral tablets for 24 or 48 weeks depending on the patient's treatment response at week 4
Study: NCT01241760
Drug: Telaprevir
Normalized name: Telaprevir
DrugBank: Telaprevir (DB05521)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 1125 mg (3 oral tablets) twice a day (every 10-14 hours) for 12 weeks
Study: NCT01241760
Drug: Pegylated interferon alfa-2a
Normalized name: Pegylated interferon alfa-2a
DrugBank: Peginterferon alfa-2a (DB00008)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 180 microgram (µg) per week, subcutaneous injection, for 24 or 48 weeks Pegylated interferon alfa-2a 180 microgram (µg) per week subcutaneous injection for 24 or 48 weeks depending on the patient's treatment response at week 4
Study: NCT01241760
Drug: Telaprevir
Normalized name: Telaprevir
DrugBank: Telaprevir (DB05521)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 750 mg (2 oral tablets) every 8 hours for 12 weeks
Study: NCT04720768
Drug: Binimetinib
Normalized name: binimetinib
DrugBank: Binimetinib (DB11967)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: MEK inhibitor
Study: NCT04720768
Drug: Encorafenib
Normalized name: encorafenib
DrugBank: Encorafenib (DB11718)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: BRAF inhibitor
Study: NCT04720768
Drug: Palbociclib
Normalized name: Palbociclib
DrugBank: Palbociclib (DB09073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: CDK4/6 inhibitor
Study: NCT01359462
Drug: tolvaptan
Normalized name: Tolvaptan
DrugBank: Tolvaptan (DB06212)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Drug: tolvaptan~tablet, 15mg, Qd, for 7 days.
Study: NCT01810588
Drug: Rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Administer one dose of 375 mg/m2 prior to or upon admission for all patients not previously exposed to rituximab or who have not received rituximab in the six months prior to transplant.
Study: NCT00219037
Drug: aliskiren
Normalized name: Aliskiren
DrugBank: Aliskiren (DB09026)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00806923
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 80mg/m2 iv on day 1 of each 3 week cycle, for a maximum of 6 cycles
Study: NCT00806923
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1250mg/m2 on days 1 and 8 of each 3 week cycle for a maximum of 6 cycles
Study: NCT00806923
Drug: bevacizumab [Avastin]
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 15mg/kg 1v on day 1 of each 3 week cycle until disease progression
Study: NCT00806923
Drug: bevacizumab [Avastin]
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 7.5 mg/kg iv on day 1 of each 3 week cycle until disease progression
Study: NCT00131456
Drug: Venlafaxine
Normalized name: Venlafaxine
DrugBank: Venlafaxine (DB00285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 375mg/day
Study: NCT00262847
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00262847
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given IV
Study: NCT03527628
Drug: Adriamycin
Normalized name: Adriamycin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 25mg/m2 Bolus injection via fast running drip of 0.9% NaCl in days 1 and 15 of each 28 day cycle.
Study: NCT03527628
Drug: Vinblastine
Normalized name: Vinblastine
DrugBank: Vinblastine (DB00570)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 6mg/m2 Intravenous infusion in 50ml sodium chloride 0.9% over 10 minutes, in days 1 and 15 of each 28 day cycle
Study: NCT03527628
Drug: Dacarbazine
Normalized name: Dacarbazine
DrugBank: Dacarbazine (DB00851)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 375mg/m2 Infusion in 500mls 0.9% NaCI over least 60mins. in days 1 and 15 of each 28 day cycle
Study: NCT03527628
Drug: Brentuximab Vedotin
Normalized name: Brentuximab Vedotin
DrugBank: Brentuximab vedotin (DB08870)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1.2mg/kg Intravenous infusion, in days 1 and 15 of each 28 day cycle
Study: NCT03527628
Drug: ABVD
Normalized name: Adriamycin, Bleomycin, Vinblastine, Dacarbazine
DrugBank: Bleomycin (DB00290)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All enrolled patients receive 2 cycles of ABVD (Adriamycin 25mg/m2, Bleomycin10,000units/m2, Vinblastine 6mg/m2 and Dacarbazine 375mg/m2)
Study: NCT01952990
Drug: Tetracaine HCl 3% and Oxymetazoline HCl 0.05%
DrugBank: Oxymetazoline (DB00935)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 spray device is 0.2mL (200 μL) in volume and contains 6mg Tetracaine HCl 3% and 0.1mg Oxymetazoline HCl. Subjects receiving the 100 μL dose will receive half of the contents of one device using a dose divider. Subjects receiving the 200 μL dose will first receive half of the contents of one device using a dose divider and then 4 minutes later will receive the 2nd half by removing the dose divider. Subjects receiving the 400 μL dose will first receive the entire contents of one device and then 4 minutes later will receive the contents of a 2nd device.
Study: NCT03823846
Drug: Routine Dezocine injection
Normalized name: DEZOCINE
DrugBank: Dezocine (DB01209)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dezocine 10mg were intramuscular injected at 8:00am, 4:00pm and 12:00pm.
Study: NCT03823846
Drug: Adjusted Dezocine injection
Normalized name: DEZOCINE
DrugBank: Dezocine (DB01209)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dezocine 10mg were intramuscular injected at at 6:00am, 2:00pm and 10:00pm.
Study: NCT01797848
Drug: Peginterferon alfa 2a
Normalized name: Peginterferon Alfa-2A
DrugBank: Interferon alfa (DB05258)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01797848
Drug: Ribavirin
Normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01797848
Drug: Placebo matching Daclatasvir
DrugBank: Daclatasvir (DB09102)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT01797848
Drug: Daclatasvir
Normalized name: Daclatasvir
DrugBank: Daclatasvir (DB09102)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT01810588
Drug: Mycophenolate Mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Will be started on Day -2 and given at a dose of 1000 mg every 8 hours until Day 28. Mycophenolae Mofetil can be given orally or intravenously. Infection, toxicity, very low patient weight (\<50 kilograms) may prompt earlier discontinuation or adjustment of doses.
Study: NCT00784485
Drug: Xolair injections
Normalized name: omalizumab Injection [Xolair]
DrugBank: Omalizumab (DB00043)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: In addition to Advair Diskus 250/50 or 500/50, subjects will receive 150 to 375 mg subcutaneous injection every 2 or 4 weeks (depending on IgE levels) for 16 weeks.
Study: NCT00238784
Drug: Budesonide/formoterol Turbuhaler
DrugBank: Formoterol (DB00983)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT02080260
Drug: regorafenib
Normalized name: Regorafenib
DrugBank: Regorafenib (DB08896)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Single agent drug therapy with regorafenib
Study: NCT00596583
Drug: DYME
Normalized name: Dymelor
DrugBank: Acetohexamide (DB00414)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2ml of 0.25 mg/ml BBG 250 in sterile ophthalmic solution
Study: NCT00596583
Drug: DYME
Normalized name: Dymelor
DrugBank: Acetohexamide (DB00414)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2ml of 0.05 mg/ml BBG 250 in sterile ophthalmic solution
Study: NCT04870541
Drug: Ondansetron 8mg
Normalized name: ONDANSETRON 8MG ORAL DISINTEGRATING TAB
DrugBank: Ondansetron (DB00904)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients receiving 8 mg of ondansetron diluted in 20 ml of 0.9% normal saline over 30 minutes as they arrive to the operating theater(75 patients).
Study: NCT04870541
Drug: Nefopam Injectable Solution
Normalized name: nefopam Injectable Solution
DrugBank: Nefopam (DB12293)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients receiving 20 mg of nefopam diluted in 20 ml of 0.9% normal saline over 30 minutes as they arrive to the operating theater (75 patients)
Study: NCT01127841
Drug: Rituximab and Bendamustine
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rituximab: 375 mg/m2/day, day 1 of each cycle, iv. Bendamustine: 90 mg/m2/day, days1 and 2 fo each cycle, iv.
Study: NCT00628589
Drug: Inhaled loxapine 5 mg
Normalized name: loxapine Inhalant Product
DrugBank: Loxapine (DB00408)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Inhaled loxapine 5 mg
Study: NCT00628589
Drug: Inhaled loxapine 10 mg
Normalized name: loxapine Inhalant Product
DrugBank: Loxapine (DB00408)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Inhaled loxapine 10 mg
Study: NCT02253823
Drug: EFV
Normalized name: Efavirenz
DrugBank: Efavirenz (DB00625)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02418312
Drug: histamine-2 receptor antagonist
DrugBank: Histamine (DB05381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: famotidine 40 mg qd plus thienopyridine
Study: NCT03627065
Drug: Parsaclisib
Normalized name: Parsaclisib
DrugBank: Parsaclisib (DB14867)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parsaclisib administered orally once daily at the protocol-defined dose.
Study: NCT02303782
Drug: Vidaza (azacitidine)
Normalized name: Vidaza
DrugBank: Azacitidine (DB00928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT01307202
Drug: Gabapentin
Normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 600mg of Gabapentin will be given orally preoperatively and 200mg for 3 times a day after surgery for 3 days
Study: NCT03483870
Drug: Morphine Sulfate
Normalized name: Morphine Sulfate
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 200 ug morphine sulphate will be injected intrathecally
Study: NCT03483870
Drug: Granisetron
Normalized name: Granisetron
DrugBank: Granisetron (DB00889)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2 mL of 2 mg granisetron IV injection
Study: NCT00003721
Drug: incyclinide
Normalized name: Incyclinide
DrugBank: Incyclinide (DB11647)
Approvals — FDA: no, EMA: no, PMDA: no
Description: This is a dose escalation study. Patients receive oral COL-3 once daily. Treatment continues in the absence of disease progression and unacceptable toxic effects. Cohorts of 3-6 patients each receive escalating doses of COL-3. Dose escalation to the next level occurs after 3 patients have completed 28 days of treatment without dose limiting toxicity (DLT). Dose escalation continues until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 or more of 6 patients experience DLT.
Study: NCT02209948
Drug: Temozolomide
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02262078
Drug: Sodium Nitrite Inhalation Solution
Normalized name: Sodium Nitrite
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 90mg of (nebulized) inhaled sodium nitrite will be administered (by inhalation) to participants prior to exercise.
Study: NCT02630017
Drug: ADHD methylphenidate first, placebo second
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: double-blind, counter-balanced administration
Study: NCT02630017
Drug: ADHD placebo first, methylphenidate second
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: double-blind, counter-balanced administration
Study: NCT02630017
Drug: Non-ADHD methylphenidate first, placebo second
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: double-blind, counter-balanced administration
Study: NCT02630017
Drug: Non-ADHD placebo first, methylphenidate second
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00289198
Drug: FF
Normalized name: MFF
DrugBank: Melphalan flufenamide (DB16627)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: fluticasone furoate 110 μg nasal spray
Study: NCT02804750
Drug: CORT125134
Normalized name: CORT125134
DrugBank: Relacorilant (DB14976)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01655381
Drug: Tocilizumab
Normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tocilizumab 8 mg/kg administered intravenously.
Study: NCT04617691
Drug: Guselkumab
Normalized name: Guselkumab
DrugBank: Guselkumab (DB11834)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Guselkumab will be administered as IV solution derived from FVP or PFS-U.
Study: NCT02767479
Drug: rabeprazole-based regimen
DrugBank: Rabeprazole (DB01129)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: This group is treated with rabeprazole 10 mg bid, AMPC 750 mg bid and CAM 200 mg bid for 1 week. Success or Failure of eradication of H. pylori is assessed by 13C-UBT 1 month after the treatment.
Study: NCT02767479
Drug: esomeprazole^based regimen
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: This group is treated with esomeprazole 20 mg bid , AMPC 750 mg bid and CAM 200 mg bid for 1 week. Success or Failure of eradication of H. pylori is assessed by 13C-UBT 1 month after the treatment.
Study: NCT03421743
Drug: Inhaled molgramostim
Normalized name: molgramostim
DrugBank: Molgramostim (DB12525)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 µg / dose molgramostim (recombinant human GM-CSF) for inhalation
Study: NCT00431951
Drug: ST-246
Normalized name: ST-246
DrugBank: Tecovirimat (DB12020)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 250 mg, 400 mg or 800 mg capsules given once daily for 21 days
Study: NCT02403895
Drug: Open-label AZD2014
Normalized name: strontium chloride, 89Sr-labeled
DrugBank: Strontium chloride Sr-89 (DB09498)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual TORC1/TORC2 inhibitor
Study: NCT02403895
Drug: paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Taxane
Study: NCT01009346
Drug: Cetuximab
Normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 250mg/m2/week
Study: NCT01009346
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 40mg/m2 Day 1, 8 every 28 days
Study: NCT01009346
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin will be administered on Day1 and Day 8 of each 28 day cycle to a target AUC of 3 over 30 minutes. Carboplatin will be dosed using the Calvert formula:~Total dose (mg) = (target AUC) x (glomerular filtration rate + 25) Creatinine clearance will be used to estimate the GFR. The Cockgroft-Gault formula will be used to estimate the creatinine clearance.
Study: NCT03990103
Drug: S1
Normalized name: LS11
DrugBank: LS11 (DB05918)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80-120 mg/day, PO, D1-14, every 21 days
Study: NCT03990103
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 20 mg/m2/day, IP, D1-3; 50 mg/m2, IV, D1; 70 mg/m2, IV, D8; every 21 days
Study: NCT03990103
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 200 mg, IP, D1, every 21 days
Study: NCT03990103
Drug: Oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 130 mg/m2, IV, D1, every 21 days
Study: NCT00313547
Drug: Quinapril 40 mg
Normalized name: quinapril 40 MG
DrugBank: Quinapril (DB00881)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00313547
Drug: Quinapril 10 mg and amlodipine 5 mg
Normalized name: quinapril 10 MG
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01100528
Drug: dacarbazine
Normalized name: Dacarbazine
DrugBank: Dacarbazine (DB00851)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV on days 1 and 29
Study: NCT00004864
Drug: GEM 231
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00004864
Drug: docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no